Combination antibody therapy for HIV treatment interruption
Treatments studied
Part of Infections clinical trials.
This study tests whether a combination of two lab-made antibodies plus an immunotherapy drug can help control HIV without daily antiretroviral pills. If successful, it might allow a safe break from your current HIV medications while keeping the virus under control.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be living with HIV and have a CD4 count above 500, which means your immune system is fairly strong.
- Your viral load (the amount of HIV in your blood) must be under 50 copies per mL for at least 15 months.
- You must be currently taking an HIV regimen that includes an integrase inhibitor or a boosted protease inhibitor.
- You must be free of other infections like hepatitis B or C, and you cannot have certain heart, autoimmune, or cancer conditions.
- You must be willing to practice safe sex (using condoms) during the study, especially during a planned break from your HIV medications.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether a combination of powerful antibodies (bNAbs) can help control HIV after stopping standard HIV treatment. Participants will pause their daily HIV medications while receiving these antibodies, and doctors will closely monitor their immune system and virus levels. It's for people who are already well-controlled on HIV treatment and have participated in a specific earlier study.
This trial tests a combination of an HIV vaccine and a new antibody treatment (GS-2872) to see if it can help control HIV without daily pills. It is for people with well-controlled HIV who are looking for ways to reduce their dependence on antiretroviral therapy.
This study tests if two lab-made antibodies can keep HIV under control when people temporarily stop their daily HIV medication. Participants will pause their antiretroviral therapy (ART) for a period and be closely monitored, with the goal of potentially finding a way to take a break from daily pills.
This trial tests whether giving two powerful HIV-fighting antibodies (called broadly neutralizing monoclonal antibodies) along with starting standard HIV medications soon after infection can help control the virus without needing daily pills. If successful, it might allow people to take a 'treatment pause' while keeping their immune system healthy.
This study tests whether adding two antibody medicines to standard HIV treatment helps people control HIV better after stopping treatment. It focuses on people with recently diagnosed (“primary”) HIV infection, aiming to improve long-term control after ART is interrupted.
This study tests a new combination of two drugs to see if they can reduce the 'hidden' HIV that stays in your body even when you're on regular HIV treatment. The goal is to work toward a cure, not just control.
Hear when a new HIV-1 trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.